LTBP1-ALK: A Novel Fusion identified in malignant pleural effusions from a patient with advanced Lung Adenocarcinoma
ALK (Anaplastic lymphoma kinase) rearrangement is the second most common targetable oncogene-dirven gene in NSCLC. It is identified in approximately 3 –7% of NSCLC patients [1], and is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, ceritinib, brigatinib [2]. EML4-ALK rearrangement was firstly identified by Soda et al. in 2007 [3]. With the development of NGS, more and more novel ALK fusion partners have been identified, such as KIF5B, STRN, KLC1, TPR, HIP1, DCTN1, CMTR1, GCC2, SEC31A and so on.
Source: Lung Cancer - Category: Cancer & Oncology Authors: HuiWen Qian, Juan Li, LiRong Zou, Cheng Ji, HaiYan Li, YuShuang Zheng, LingChuan Guo, WeiDong Zhu, Yi Zhang Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer